Mineralocorticoid Receptor Antagonists in Type 2 Diabetes
Diabetes Type 2

About this trial
This is an interventional treatment trial for Diabetes Type 2
Eligibility Criteria
Inclusion Criteria:
- Able to understand the written patient information and to give informed consent
- Type 2 diabetes mellitus (WHO criteria), diagnosed at least 3 months prior to baseline
- Blood pressure treatment according to standard guidelines
- Negative pregnancy test (fertile women)
- Be willing to change/pause potassium sparing medication
- Age 18-85 years
- Patients must have high cardiovascular risk factors, defined as one of the following:
NT-proBNP ≥ 70 pg/ml (taken within the last 6 months prior to baseline) Albuminuria ( albumin/creatinine ratio ≥ 30 mg/g Confirmed history of myocardial infarction (≥ 3 months prior to baseline) Or patient discharged from hospital with a documented diagnosis of unstable angina within 24 months prior to baseline Evidence of coronary artery disease by CAG in 1 or more major coronary arteries OR at least one of the following: a positive noninvasive stress test, OR a positive stress echocardiography showing regional systolic wall motion abnormalities, OR a positive scintigraphy test showing stress-induced ischemia History of ischemic or hemorrhagic stroke (≥ 3 months prior to informed consent) Presence of peripheral artery disease (symptomatic or not ) documented by either: previous limb angioplasty, stenting or bypass surgery; or previous limb or foot amputation due to circulatory insufficiency; or angiographic evidence of significant (≥ 50%) peripheral artery stenosis in at least one limb; or evidence from a non-invasive measurement of significant (≥50% or as reported as hemodynamically significant) peripheral artery stenosis in at least one limb; or ankle brachial index of ≤ 0.9
Left ventricle hypertrophy:
Documented at echocardiography ECG: R-spike in V5/V6 ≥ 25 mm or S-spike in V1 + R-spike in V5/V6 ≥ 35 mm Patients both with and without a cardiovascular risk factor can be randomized to the fat biopsy sub study.
Exclusion Criteria:
- Allergic to the study medication
- Systolic HF (LVEF ≤ 40%)
- Impaired kidney function, eGFR ≤ 40 ml/min
- Severe liver insufficiency (Child-Pugh class C)
- Treatment with MR antagonist within 3 months prior to baseline
- Treatment with both ACE inhibitors and Angiotensin II Receptor blockers.
- Serum-potassium ≥ 5.0 mmol/l
- Serum-sodium ≤ 135 mmol/l
- Myocardial infarction, unstable angina pectoris or bypass graft surgery within 3 months prior to baseline
- Persistant atrial fibrillation (except for the fat biopsy sub population)
- ECG showing malign ventricular arrhythmia or prolonged QT-interval (> 500ms)
- Untreated heart valve disease
- ICD-unit/pacemaker
- Pregnancy or desire hereof or breastfeeding
- Women in the fertile age not using safe contraceptives (spiral, hormonal contraceptives)
- Cancer unless complete remission ≥ 5 year
- Alcohol-/drug-abuse
- Inflammatory bowel disease
- Other concomitant disease or treatment that according to the investigator's assessment makes the patient unsuitable to participate in the study
- Simultaneous participation in another clinical study
- Treatment with CYP3A4-inhibitors (e.g. itraconazol, etoconazol, ritonavir, nelfinavir, clarithromycin, telithromycin and nefazodon)
Sites / Locations
- Herlev and Gentofte Hospital, Department of Endocrinology and Metabolism, Department of internal medicine,
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Eplerenone
placebo
Eplerenone 50 mg tablets. 2-4 tablets once daily for 26 weeks
sugar pill manufactured to mimic Eplerenone 50 mg tablet. 2-4 tablets once daily for 26 weeks.